Biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday that it is set to present key findings from its solid tumour pipeline at the European Society for Medical Oncology (ESMO) Congress 2024, including data on mirvetuximab soravtansine (ELAHERE) and c-Met targeting antibody-drug conjugates (ADCs) Teliso-V and ABBV-400. The company's ADCs are designed to target biomarkers such as folate receptor-alpha (FRα) and c-Met, associated with poor prognosis in various cancers.
Data from the Phase 2 PICCOLO trial of mirvetuximab soravtansine showed a 51.9% objective response rate in heavily pre-treated patients with FRα-positive platinum-sensitive ovarian cancer (PSOC), with a median duration of response of 8.3 months. The safety profile was consistent with previous studies, with no new concerns reported.
Exploratory patient-reported outcomes from the Phase 2 LUMINOSITY trial of Teliso-V, a c-Met targeting ADC, in advanced non-small cell lung cancer (NSCLC) will also be presented. Additionally, new safety and efficacy data for ABBV-400, a next-generation c-Met ADC, demonstrated antitumor activity in pre-treated NSCLC and gastroesophageal cancer patients.
AbbVie's robust oncology portfolio continues to evolve with a focus on addressing high unmet needs in solid tumours, advancing targeted therapies across multiple cancer types.
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024